Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05630677 · ClinicalTrials.gov registry record · Phase 1
A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT05630677 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 21 participants.
The verdict
NCT05630677, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study will estimate the relative bioavailability of AZD5055 film-coated tablet as compared to AZD5055 oral suspension. The study will also assess the absolute bioavailabilty of AZD5055 and the effect of food and an acid reducing agent, rabeprazole, on the PK of AZD5055 film-coated tablets when given with food (fed state) or without food (fasted state).
Interventions
- DRUG AZD5055 solution for infusion
- DRUG AZD5055 oral suspension
- DRUG AZD5055 film-coated tablet
- DRUG Rabeprazole, Delayed-release tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2022-11-04 |
| Est. Completion | 2023-02-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05630677
The ClinicalTrials.gov registry entry for NCT05630677 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which AZD5055 solution for infusion is the first listed.
NCT05630677 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05630677 about?
NCT05630677 is a clinical study titled "A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.". This study will estimate the relative bioavailability of AZD5055 film-coated tablet as compared to AZD5055 oral suspension. The study will also assess the absolute bioavailabilty of AZD5055 and the effect of food and an acid reducing agent, rabeprazole, on the PK of AZD5055 film-coated tablets when ...
What is the current status of trial NCT05630677?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2022-11-04. Estimated completion is 2023-02-09.
What interventions are being tested in trial NCT05630677?
The interventions under investigation include: AZD5055 solution for infusion (DRUG), AZD5055 oral suspension (DRUG), AZD5055 film-coated tablet (DRUG), Rabeprazole, Delayed-release tablet (DRUG).
Who is sponsoring clinical trial NCT05630677?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.